Atropine poisoning

•

2 likes•1,426 views

In this presentation there is a discussion on very rare topic of atropine poisoning with brief introduction , nomenclature , toxic concentration of tropane alkaloids ,pathophysiology of poisoning , intoxication , causes of poisoning , clinical symptoms , diagnosis and treatment .

Health & Medicine

A
T
R
O
P
I
N
E
P
O
I
S
O
N
I
N
G
By:- Shailja Sharma
Assistant Professor
Pharmacology

References
• Google images
• Slide share

We all are familiar with the poisonous nature of lead metal .Sources of contamination , lead exposure pathways ,health effects, preventive strategies ,individual level strategies ,diagnosis , management ,preventive measures , treatment both after acute and chronic attacks are discussed . These all topics will help the Researchers , scholars , educators and learners in developing their basic concepts about the topic.

ENDOCRINE SYSTEM (Classification of hormones -4 Types)

Shailja Sharma

What's hot

Drugs for Congestive Heart Failure

SMS MEDICAL COLLEGE

Sympathomimetic

Viraj Shinde

Sympatholytics

Sadaqat Ali

Narcotics and non narcotics analgesics

FarazaJaved

Organophosphate poisoning and its management (Clinical Toxicology)

Soujanya Pharm.D

Anticholinergic drugs

DrVishal Kandhway

general anaesthesia

Uttara Joshi

Antidiabetic drugs

Subramani Parasuraman

Pharmacology of Plasma expanders

Koppala RVS Chaitanya

Local anaesthetics

OPTOM FASLU MUHAMMED

Antiarrhythmic drugs bds

Naser Tadvi

Anticholinesterases

Kanav Bhanot

Sympathomimetics and blockers

Dr Pralhad Patki

Effects of drugs on rabbit ileum

kopalsharma85

Antidiabetic drugs

Dr. Pramod B

Sympathomimetic Drugs

Shagufta Farooqui

Antianginal Drugs

Subramani Parasuraman

Antihistamines - Pharmacology

Areej Abu Hanieh

Antiepileptics

Kalaivanisathishr

Adrenaline pharmacology

PARUL UNIVERSITY

What's hot (20)

Drugs for Congestive Heart Failure

Sympathomimetic

Sympatholytics

Narcotics and non narcotics analgesics

Organophosphate poisoning and its management (Clinical Toxicology)

Anticholinergic drugs

general anaesthesia

Antidiabetic drugs

Pharmacology of Plasma expanders

Local anaesthetics

Antiarrhythmic drugs bds

Anticholinesterases

Sympathomimetics and blockers

Effects of drugs on rabbit ileum

Antidiabetic drugs

Sympathomimetic Drugs

Antianginal Drugs

Antihistamines - Pharmacology

Antiepileptics

Adrenaline pharmacology

More from Shailja Sharma

Lead poisoning & its treatment

Shailja Sharma

ENDOCRINE SYSTEM (Classification of hormones -4 Types)

Shailja Sharma

Barbiturate poisoning

Shailja Sharma

Arsenic poisoning and antidotes

Shailja Sharma

Pharmacology of Antimalarial agents & Antimalarial Therapy

Shailja Sharma

In this PPT there is a short discussion over anti malarial agents followed by a short discussion on lifecycle of plasmodium , classification of antimalarial agents ,various quinine based drugs such Mefloquine , Atovaquone , Pyrimethamine , Primaquine are discussed in brief with reference to their half-life , mechanism of action, pharmacokinetics and pharmacodynamics characters . Side effects of the antimalarial agents are also stated. There is also a note over the antimalarial Therapy with lifecycle of parasite.

Pharmacology of Anti leprotic Agents

Antihelmentic agents

Antifungal agents

Antiamoebic agents

Anti viral basics

Monera

Introduction to covid 19

Shailja Sharma

Adrenal gland

Shailja Sharma

More from Shailja Sharma (13)

Lead poisoning & its treatment

ENDOCRINE SYSTEM (Classification of hormones -4 Types)

Barbiturate poisoning

Arsenic poisoning and antidotes

Pharmacology of Antimalarial agents & Antimalarial Therapy

Pharmacology of Anti leprotic Agents

Antihelmentic agents

Antifungal agents

Antiamoebic agents

Anti viral basics

Monera

Introduction to covid 19

Adrenal gland

Recently uploaded

Cervical & Brachial Plexus By Dr. RIG.pptx

Dr. Rabia Inam Gandapore

basicmodesofventilation2022-220313203758.pdf

aljamhori teaching hospital

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Oleg Kshivets

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists

Saeid Safari

New Drug Discovery and Development .....

NEHA GUPTA

The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.

Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

How to Give Better Lectures: Some Tips for Doctors

LanceCatedral

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx

Dr. Rabia Inam Gandapore

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf

Anujkumaranit

BRACHYTHERAPY OVERVIEW AND APPLICATORS

Krishan Murari

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Savita Shen $i11

Ocular injury ppt Upendra pal optometrist upums saifai etawah

pal078100

Prix Galien International 2024 Forum Program

Levi Shapiro

June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels: - ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING - WOMEN’S HEALTH: FERTILITY PRESERVATION - WHAT’S NEW IN THE TREATMENT OF INFECTIOUS, ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES? - ARTIFICIAL INTELLIGENCE AND ETHICS - GENE THERAPY - BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE - ETHICAL CHALLENGES IN LIFE SCIENCES - Prix Galien International Awards Ceremony

Superficial & Deep Fascia of the NECK.pptx

Dr. Rabia Inam Gandapore

POST OPERATIVE OLIGURIA and its management

touseefaziz1

Are There Any Natural Remedies To Treat Syphilis.pdf

Little Cross Family Clinic

Knee anatomy and clinical tests 2024.pdf

vimalpl1234

heat stroke and heat exhaustion in children

SumeraAhmad5

Ophthalmology Clinical Tests for OSCE exam

KafrELShiekh University